{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:41:30Z","timestamp":1780393290970,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ecl.2021.03.010","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T18:16:41Z","timestamp":1621448201000},"page":"179-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Update on Approved Osteoporosis Therapies Including Combination and Sequential Use of Agents"],"prefix":"10.1016","volume":"50","author":[{"given":"Dominik","family":"Saul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ecl.2021.03.010_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.010_bib2","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.clinthera.2015.06.006","article-title":"The pathophysiology and treatment of osteoporosis","volume":"37","author":"Drake","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.ecl.2021.03.010_bib3","series-title":"Endotext","article-title":"The epidemiology and pathogenesis of osteoporosis","author":"Rosen","year":"2020"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.010_bib4","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.37765\/ajmc.2020.43156","article-title":"Economic burden of osteoporotic fractures in US managed care enrollees","volume":"26","author":"Williams","year":"2020","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.010_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: the United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.010_bib6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.010_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.ecl.2021.03.010_bib8","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9041","key":"10.1016\/j.ecl.2021.03.010_bib9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ecl.2021.03.010_bib10","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ecl.2021.03.010_bib11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.010_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.010_bib13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"issue":"18","key":"10.1016\/j.ecl.2021.03.010_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.ecl.2021.03.010_bib15","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.010_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.010_bib17","doi-asserted-by":"crossref","first-page":"dgaa062","DOI":"10.1210\/clinem\/dgaa062","article-title":"Ten years of very infrequent zoledronate therapy in older women: an open-label extension of a randomized trial","volume":"105","author":"Grey","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.010_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.010_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.010_bib20","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.010_bib21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.010_bib22","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1210\/jc.2017-02669","article-title":"Effects of long-term denosumab on bone histomorphometry and mineralization in women with postmenopausal osteoporosis","volume":"103","author":"Dempster","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2021.03.010_bib23","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.010_bib24","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.010_bib25","first-page":"289","article-title":"Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study","volume":"86","author":"Khastgir","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.010_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMcp1714787","article-title":"Hormone therapy for postmenopausal women","volume":"382","author":"Pinkerton","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.010_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41467-019-14003-6","article-title":"Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism","volume":"11","author":"Weivoda","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ecl.2021.03.010_bib28","doi-asserted-by":"crossref","first-page":"115516","DOI":"10.1016\/j.bone.2020.115516","article-title":"Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches","author":"Langdahl","year":"2020","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.010_bib29","doi-asserted-by":"crossref","first-page":"dgaa007","DOI":"10.1210\/clinem\/dgaa007","article-title":"Which drug next? sequential therapy for osteoporosis","volume":"105","author":"Lukert","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.ecl.2021.03.010_bib30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"10117","key":"10.1016\/j.ecl.2021.03.010_bib31","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"10133","key":"10.1016\/j.ecl.2021.03.010_bib32","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(18)30754-2","article-title":"Teriparatide vs risedronate for osteoporosis","volume":"391","author":"Liel","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.010_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.010_bib34","first-page":"JCO1902192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","author":"Sim","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ecl.2021.03.010_bib35","series-title":"Assessment report Eladynos: international non-proprietary name: abaloparatide. [Procedure No. EMEA\/H\/C\/004157\/0000]","year":"2018"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.010_bib36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.010_bib37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.2016.11032","article-title":"Osteoporosis therapy in postmenopausal women with high risk of fracture","volume":"316","author":"Cappola","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.010_bib38","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24\u00a0months of alendronate after 18\u00a0months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.010_bib39","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1210\/clinem\/dgz162","article-title":"Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis","volume":"105","author":"Leder","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2021.03.010_bib40","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.clinthera.2020.04.012","article-title":"Effect of abaloparatide on bone mineral density and fracture incidence in a subset of younger postmenopausal women with osteoporosis at high risk for fracture","volume":"42","author":"Saag","year":"2020","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.010_bib41","doi-asserted-by":"crossref","first-page":"e10346","DOI":"10.1002\/jbm4.10346","article-title":"Abaloparatide in postmenopausal women with osteoporosis and type 2 diabetes: a post hoc analysis of the ACTIVE Study","volume":"4","author":"Dhaliwal","year":"2020","journal-title":"JBMR Plus"},{"issue":"12","key":"10.1016\/j.ecl.2021.03.010_bib42","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"16","key":"10.1016\/j.ecl.2021.03.010_bib43","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.010_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMc1615367","article-title":"Romosozumab treatment in postmenopausal osteoporosis","volume":"376","author":"Kalyan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ecl.2021.03.010_bib45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.010_bib46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc1714810","article-title":"Romosozumab versus alendronate and fracture risk in women with osteoporosis","volume":"378","author":"Tsourdi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.010_bib47","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A\u00a0Phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.010_bib48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide rhPTH(1-34) in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.010_bib49","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2021.03.010_bib50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","article-title":"Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial","volume":"7","author":"Tsai","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.010_bib51","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2021.03.010_bib52","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1210\/jc.2019-00924","article-title":"Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use","volume":"104","author":"Lyu","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.010_bib53","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9999","key":"10.1016\/j.ecl.2021.03.010_bib54","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"10102","key":"10.1016\/j.ecl.2021.03.010_bib55","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ecl.2021.03.010_bib56","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2021.03.010_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3996","article-title":"T-Score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial","author":"Cosman","year":"2020","journal-title":"J\u00a0Bone Miner Res"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:45:19Z","timestamp":1760175919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852921000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0889852921000220"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2021.03.010","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Approved Osteoporosis Therapies Including Combination and Sequential Use of Agents","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2021.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}